CLINICAL AND ECONOMIC ANALYSIS OF USING OF LONG ACTION ERYTHROPOES STIMULATED AGENTS FOR THE TREATMENT OF ANEMIA CKD V HD PATIENTS
Journal: Ukrainian Journal of Nephrology and Dialysis (Vol.3, No. 47)Publication Date: 2015-10-05
Authors : M. Kolesnyk; N. Bezdetko; V. Novakivskyy;
Page : 65-70
Keywords : pharmacoeconomic; anemia; ESA (erythropoes stimulated agents); hemodialysis; hemodiafiltration; pegilated erythropoietin - p; darbopoietin - a; Darbepoetin; long - сcontinuous erythropoietin receptor activator (CERA); chronic kidney diseases (CKD).;
Abstract
The article describes the ways to cost optimization of anemia treatment CKD - HD patients. Aims. dinical and economic analysis treatment of Anemia CKD VHD PTS with using long action Erythropoiesis Stimulating Agents (ESA). Methods. We calculated the true cost of anemia therapy with darbepoetin alfa compared to the methoxypolyethyleneglycol - epoetin beta. Results. It was established that average cost of therapy with methoxypolyethyleneglycol - epoetin beta was lower than darbepoetin alfa provided declared, wholesale or retail prices of25 - 60%. Conclusions. The methoxypolyethyleneglycol - epoetin beta haspharmacoeconomics advantages in comparison with the darbepoetin alfa in treatment of anemia CKD V HD patients.
Other Latest Articles
- INDICATORS OF OXIDATIVE STRESS AND RESISTANCE OF ERYTHROCYTES IN PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE VD DEPENDING ON MODALITY OF RENAL REPLACEMENT THERAPY
- THE STATUS OF NO - SYNTHASE/ARGINASE SYSTEM AND OXIDATIVEPROCESSES IN LYMPHOCYTESLYSATEINBLOOD OF PATIENTS WITHDIABETICNEPHROPATHY AFTER THE SESSION OF HEMODIALYSIS
- FEATURES MANAGING PATIENTS WITH DIABETIC NEPHROPATHY WITH SECONDARYHYPERTENSION IN THE PRACTICE DOCTOR OF GENERAL PRACTITIONERS AND FAMILY MEDICINE
- CLINICAL AND MORPHOLOGICAL COMPARISON AT NEPHROPATHY IN PATIENTS WITH MICROSCOPIC POLYANGIITIS
- RENAL RISCS IN DETERMINATION OF BRONCHIAL ASTHMA PHENOTYPES
Last modified: 2018-09-12 19:24:10